About Imvax
Imvax is a company based in Philadelphia (United States) founded in 2015 by David Andrews. Imvax has raised $203.83 million across 5 funding rounds from investors including Magnetar Capital, Invus and TLP Investments. The company has 50 employees as of December 31, 2021. Imvax offers products and services including IGV-001, Goldspire Platform, IHC-001, and IUC-001. Imvax operates in a competitive market with competitors including GT Medical Technologies, Basilea, BriaCell Therapeutics, Laminar Pharma and SOM Biotech, among others.
- Headquarter Philadelphia, United States
- Employees 50 as on 31 Dec, 2021
- Founders David Andrews
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Imvax, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$203.83 M (USD)
in 5 rounds
-
Latest Funding Round
$29 M (USD), Series C
Jan 29, 2025
-
Investors
Magnetar Capital
& 4 more
-
Employee Count
50
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Imvax
Imvax offers a comprehensive portfolio of products and services, including IGV-001, Goldspire Platform, IHC-001, and IUC-001.
Treats newly diagnosed glioblastoma through clinical trials
Captures tumor antigens for personalized cancer treatments
Preclinical treatment for solid tumors
Targets various solid tumor applications
People of Imvax
Unlock access to complete
Unlock access to complete
Funding Insights of Imvax
Imvax has successfully raised a total of $203.83M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $29 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $29.0M
-
First Round
First Round
(16 Jun 2017)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series C - Imvax | Valuation |
investors |
|
| Sep, 2023 | Amount | Series C - Imvax | Valuation |
investors |
|
| Jul, 2020 | Amount | Series C - Imvax | Valuation | HP Wild Holding |
Investors in Imvax
Imvax has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Magnetar Capital, Invus and TLP Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Magnetar Capital is engaged in alternative asset management.
|
Founded Year | Domain | Location | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Imvax
Financial Statements - Imvax
Imvax Comparisons
Competitors of Imvax
Imvax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GT Medical Technologies, Basilea, BriaCell Therapeutics, Laminar Pharma and SOM Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Medical devices for brain tumor radiation therapy are provided.
|
|
| domain | founded_year | HQ Location |
Antibiotics, antifungals, and oncology drugs are developed for disease treatment.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of cancer
|
|
| domain | founded_year | HQ Location |
Melipathy-based drugs are developed for cancer, Alzheimer's, and inflammation treatments.
|
|
| domain | founded_year | HQ Location |
Developer of platform for screening compounds to treat rare diseases
|
Frequently Asked Questions about Imvax
Imvax was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Imvax is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Imvax is a funded company, having raised a total of $203.83M across 5 funding rounds to date. The company's 1st funding round was a Series C of $112.37M, raised on Jun 16, 2017.
As of Dec 31, 2021, the latest employee count at Imvax is 50.
Imvax was founded in 2015 and is headquartered in Philadelphia, United States. Patient-specific vaccines and immunotherapies targeting malignant gliomas and other cancers are developed by the company within the biotechnology sector. The lead product, IGV-001, an autologous tumor cell vaccine designed to activate immune responses against cancer cells, is undergoing phase 1 clinical trials.
Imvax's top competitors include GT Medical Technologies, BriaCell Therapeutics and Basilea.
Imvax offers IGV-001, Goldspire Platform, IHC-001, and IUC-001.
Imvax has 5 investors. Key investors include Magnetar Capital, Invus, TLP Investments, HP Wild Holding, and Ziff Capital Partners.